dMed Biopharmaceutical Co., Ltd., a Chinese full service Clinical Contract Research Organization (CRO), announces on Wednesday that it has completed nearly US$50 million in a series B financing round.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?